Hematologic Malignancies

描述(由申请人提供)：这是一份关于“恶性血液病”会议的部分资金申请，该会议由美国实验生物学联合会(FASE B)主办，于2003年7月26-31日在佛蒙特州萨克森河的佛蒙特学院举行。将有九个主要会议和三个海报会议。参与将限于175名科学家申请者，他们将根据他们的专业知识和兴趣被选为最有可能为刺激和富有成效的交流做出贡献的人。主要焦点将放在造血谱系确定的组成部分和机制上，这一点将在主旨演讲中得到强调。其他将包括的讨论主题包括：干细胞生物学与发育性造血；染色体易位产物的作用机制；造血细胞中的正常和病理信号；异常转录调控；细胞周期变化；白血病和淋巴瘤中的凋亡、分化和有丝分裂通路的解除调控；血液系统恶性肿瘤的基因组学；激酶抑制剂和其他实验疗法；以及翻译研究。使用动物模型系统来分析血液癌基因的生物学功能，并作为临床前模型来测试实验药物将是另一个关键课题。会议将包括一场关于应用于恶性血液病的基因组学技术的会议，特别关注如何利用这些信息来制定新的治疗方法。这次会议的一个主要目的是将分子生物学家、生物化学家、遗传学家和临床医生聚集在一起。对造血肿瘤发生机制的分析为在不同研究领域拥有专业知识的基础科学家提供了一个独特的机会，让他们与熟悉与各种临床疾病相关的表型的临床医生交流意见。在过去关于这一主题的会议上，交流的信息形成了新的研究途径。因此，拟议中的会议可能会产生治疗血液系统恶性肿瘤的新治疗策略的开发。

DESCRIPTION (provided by applicant): This is an application for partial funding of a conference on "Hematologic Malignancies" being held under the auspices of the Federation of American Societies for Experimental biology (FASEB) from July 26-31, 2003 at the Vermont Academy in Saxons River, VT. There will be nine major sessions and three poster sessions. Participation will be limited to 175 scientists applicants who will be selected on the basis of their expertise and interests as most likely to contribute to a stimulating and productive interchange. A major focus will be on the components and mechanisms of hematopoietic lineage determination, which will be highlighted by the keynote address. Among other topics to be included for discussion are: stem cell biology and developmental hematopoiesis; mechanisms of action of the products of chromosomal translocations; normal and pathologic signaling in hematopoietic cells; aberrant transcriptional control; cell cycle alternations; deregulation of apoptotic, differentiation and mitogenic pathways in leukemias and lymphomas; genomics of hematological malignancies; kinase inhibitor and other experimental therapeutics; and translational research. The use of animal model systems to analyze the biological functions of hematologic oncogenes and as preclinical models for testing experimental drugs will be another key topic. The conference will include a session on genomics technologies as applied to hematologic malignancies with a particular focus on potential ways to utilize this information towards the formulation of novel therapies. A major purpose of the meeting is to bring together molecular biologists, biochemists, geneticists, and clinicians. Analysis of the mechanisms underlying the development of hematopoietic neoplasms provides a unique opportunity for basic scientists with expertise in distinct areas of research to exchange ideas with clinicians who are familiar with the phenotypes associated with the various clinical disorders. In past conferences on this topic, new avenues of research have emerged from the information exchanged. Thus, the development of novel therapeutic strategies in the treatment of hematopoietic malignancies is likely to emerge from the proposed meeting.